Having covered trial phases, sample size, placebo controls, peer review, and replication individually, it's useful to pull those criteria together into a single framework for comparing peptides against each other directly.
A Simple Evidence Checklist
For any peptide, it's worth asking: has it completed Phase 3 human trials? Do placebo-controlled human studies exist at all? Has any finding been independently replicated by more than one research group? Is there an FDA-approved label, or approval in another major regulatory jurisdiction? Answering these questions for a specific compound gives a much clearer evidence picture than its general popularity or marketing claims.
Where the Compounds on This Site Fall
Using this framework, semaglutide, tirzepatide, and liraglutide sit at the strongest end, with completed Phase 3 programs, large placebo-controlled trials, and FDA approval. Bremelanotide and sermorelin (historically) also cleared full approval processes, if for narrower populations. Compounds like kisspeptin-10 and thymosin alpha-1 have real institutional research interest and some controlled human data, without full FDA approval domestically. Retatrutide sits mid-process, in active Phase 3 trials. Selank and Semax have real approved status, just in a different regulatory system. And compounds like BPC-157, TB-500, Epithalon, DSIP, and the various growth hormone secretagogues sit at the weaker end, relying primarily on animal, cell-culture, or small, dated, or non-replicated human studies.
Why This Comparison Is Useful
Laying these compounds out side by side on the same evidence criteria makes clear that "peptide" is not a single evidence tier, the gap between the strongest and weakest end of this spectrum is enormous, even though marketing language often treats all of them with similar confidence.
Applying This Framework Yourself
This same checklist works for any peptide not specifically covered on this site: trial phase, placebo control, independent replication, and regulatory status. Running any new compound you encounter through these same four questions is a reliable way to locate it honestly on this spectrum, rather than taking a vendor's or forum's characterization at face value.
This Framework Will Keep Changing
It's worth remembering that this evidence landscape isn't static. Retatrutide could complete its trial program and reach approval, a compound like BPC-157 could eventually generate real controlled human trials, and today's confident consensus about an approved drug's safety profile can still shift as more post-market data accumulates, discussed in this site's guide to long-term data gaps. Revisiting this same four-question framework periodically for any compound you're following is a more reliable habit than treating any single snapshot as permanent.